Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe - an update of the European Union Drugs Agency technical protocol, 2024.

IF 7.8 2区 医学 Q1 INFECTIOUS DISEASES
Ida Sperle, Thomas Seyler, Filippo Pericoli, Erika Duffell, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kåberg, Anda Ķīvīte-Urtāne, Carole Seguin-Devaux, Vana Sypsa, Ruth Zimmermann
{"title":"Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe - an update of the European Union Drugs Agency technical protocol, 2024.","authors":"Ida Sperle, Thomas Seyler, Filippo Pericoli, Erika Duffell, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kåberg, Anda Ķīvīte-Urtāne, Carole Seguin-Devaux, Vana Sypsa, Ruth Zimmermann","doi":"10.2807/1560-7917.ES.2025.30.30.2500007","DOIUrl":null,"url":null,"abstract":"<p><p>Drug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which covers all steps from planning to data analysis needed for a survey among PWID. Drug-related infectious disease-specific indicators were revised. To enable a more effective monitoring of the current epidemiological situation, we added specific core indicators, such as prevalence of viraemic HBV, HCV and HIV care cascades and harm reduction-related indicators. HIV pre-exposure prophylaxis and take-home naloxone were added as optional indicators. The process was informed by a European working group, who shared best-practice examples of (repeated) cross-sectional and cohort surveys using different methods in various settings. To reach the World Health Organization's goal of ending HIV and the viral hepatitis epidemics, comprehensive DRID monitoring among the disproportionately affected PWID population is needed.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 30","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315514/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.30.2500007","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Drug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which covers all steps from planning to data analysis needed for a survey among PWID. Drug-related infectious disease-specific indicators were revised. To enable a more effective monitoring of the current epidemiological situation, we added specific core indicators, such as prevalence of viraemic HBV, HCV and HIV care cascades and harm reduction-related indicators. HIV pre-exposure prophylaxis and take-home naloxone were added as optional indicators. The process was informed by a European working group, who shared best-practice examples of (repeated) cross-sectional and cohort surveys using different methods in various settings. To reach the World Health Organization's goal of ending HIV and the viral hepatitis epidemics, comprehensive DRID monitoring among the disproportionately affected PWID population is needed.

标准化欧洲注射吸毒者药物相关传染病监测数据——2024年欧盟药品管理局技术议定书的更新。
艾滋病毒、乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)等与药物有关的传染病(DRID)造成注射吸毒者(PWID)的高发病率和死亡率。欧洲联盟药品管理局(EUDA)负责监测欧洲的DRID和PWID的相关行为。我们更新了EUDA DRID技术协议,该协议涵盖了PWID调查所需的从规划到数据分析的所有步骤。修订了与药物有关的传染病特定指标。为了能够更有效地监测当前的流行病学情况,我们增加了具体的核心指标,如病毒性HBV、HCV和HIV级联护理的流行率以及与减少危害相关的指标。增加HIV暴露前预防和纳洛酮带回家作为可选指标。该过程由一个欧洲工作组提供信息,该工作组分享了在不同环境下使用不同方法进行(重复)横断面和队列调查的最佳实践示例。为了实现世界卫生组织关于结束艾滋病毒和病毒性肝炎流行的目标,需要对受严重感染的艾滋病患者进行全面的艾滋病监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Eurosurveillance
Eurosurveillance INFECTIOUS DISEASES-
CiteScore
32.70
自引率
2.10%
发文量
430
审稿时长
3-8 weeks
期刊介绍: Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信